Avascular Necrosis Global Market Report 2025

The avascular necrosis market size has grown strongly in recent years. It will grow from $0.81 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to several factors, including the increasing aging population, rising levels of alcohol consumption, expansion of sports medicine, growth in medical tourism, and advancements in precision medicine.

The avascular necrosis market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth during the forecast period can be credited to the increasing incidence of corticosteroid-induced osteonecrosis, a rising number of knee replacements and hip surgeries, a surge in drug approvals, a higher rate of road accidents, and a growing prevalence of bone injuries. Key trends expected in the forecast period include technological innovations, advancements in imaging technologies, AI-driven diagnostic solutions, 3D-printed surgical implants, regenerative orthobiologics, and cellular therapies.

The increasing number of knee and hip replacement surgeries is anticipated to drive the growth of the avascular necrosis market in the coming years. Knee and hip replacements are surgical procedures aimed at replacing damaged joints and alleviating pain in severe cases of avascular necrosis. This rise in surgical procedures is largely due to the growing incidence of osteoarthritis, a condition that leads to intense joint pain and impaired mobility, often necessitating surgical intervention to enhance quality of life. Avascular necrosis plays a significant role in creating the need for such surgeries, as it causes the death of bone tissue from reduced blood flow, which frequently results in joint collapse and deterioration. For example, in September 2023, Curvo Labs, Inc., a U.S.-based healthcare technology firm, reported that knee replacement procedures in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Thus, the rising number of knee and hip replacements is fueling the growth of the avascular necrosis market.

The increasing healthcare expenditure is projected to support the growth of the avascular necrosis market in the future. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related products within a given population or healthcare system. This expenditure is rising due to the growing prevalence of chronic illnesses, which demand ongoing management, repeated hospital visits, and expensive medications. In the context of avascular necrosis, higher healthcare spending facilitates access to early diagnosis, advanced therapeutic options, and surgical interventions that aid in managing the condition and improving patient outcomes. For example, in April 2025, the American Medical Association, a U.S.-based organization representing physicians and medical students, reported that health spending in the U.S. rose by 7.5% in 2023 to $4.9 trillion, or $14,570 per person, up from a 4.6% increase in 2022. Hence, the rise in healthcare expenditure is contributing to the growth of the avascular necrosis market.

Leading companies in the avascular necrosis market are securing regulatory approvals to broaden their product offerings, improve treatment alternatives, and reinforce their market position. Regulatory approvals are official authorizations granted by health authorities, allowing a medical product or therapy to be marketed and used after demonstrating compliance with safety and efficacy standards. For example, in May 2022, Regrow Biosciences, a biotechnology company based in India, received approval from the United States Food and Drug Administration to initiate Phase II clinical trials in the U.S. for OSSGROW, an orphan drug intended for the treatment of osteonecrosis (avascular necrosis). OSSGROW is an innovative, patient-specific bone cell therapy developed by Regrow Biosciences for the curative treatment of early to moderate stages (up to Stage III) of avascular necrosis. The treatment involves collecting the patient’s bone marrow, isolating mesenchymal stem cells, and culturing them in a specialized lab to generate osteoblasts - cells responsible for forming bone. OSSGROW is regarded as a natural, safe, and potentially long-term solution designed to replace conventional therapies and joint replacement surgeries that only alleviate symptoms.

Major players in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healthcare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc., Ginger Healthcare Private Limited.

North America was the largest region in the avascular necrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in avascular necrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the avascular necrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Avascular necrosis (AVN) is a condition characterized by the death of bone tissue due to an insufficient blood supply. When blood flow to a bone is reduced or interrupted, bone cells begin to deteriorate, ultimately leading to the collapse of the bone structure and potential joint damage. The condition may arise from factors such as physical trauma, prolonged steroid use, excessive alcohol intake, or certain underlying medical conditions.

Avascular necrosis is primarily classified into trauma-related and non-trauma-related avascular necrosis. Trauma-related AVN develops following bone injuries like fractures or joint dislocations, which obstruct blood circulation and lead to bone tissue death. Diagnosis methods for AVN include imaging techniques, biopsies, computed tomography (CT) scans, positron emission tomography (PET), and X-rays. Treatment options range from medication and surgery to physical therapy, lifestyle modifications, and bone grafting. The condition is managed across various healthcare settings, including hospitals, specialty clinics, rehabilitation centers, ambulatory surgical centers, and home care environments.

The avascular necrosis market research report is one of a series of new reports that provides avascular necrosis market statistics, including avascular necrosis industry global market size, regional shares, competitors with an avascular necrosis market share, detailed avascular necrosis market segments, market trends and opportunities, and any further data you may need to thrive in the avascular necrosis industry. This avascular necrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The avascular necrosis market consists of revenues earned by entities by providing services such as radiology services, pharmacotherapy management services, long-term preventive treatment, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The avascular necrosis market also includes sales of products, including bone graft materials, orthopedic implants, C1 esterase inhibitors, and platelet-rich plasma kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.